There are, however, three single-case reports of BRAF p.V600E positive posterior pituitary tumors (two with confirmed NKX2-1-expression) treated with dabrafenib, either alone [55] or combined with cobimetinib [56] or trametinib [57]. The gene discussed is BRAF; the disease is posterior pituitary gland neoplasm.